Cidara Therapeutics Announces Two Presentations On Innovative Drug-Fc Conjugate, CD388, At The 2024 OPTIONS XII For The Control Of Influenza Conference
Cidara Therapeutics Announces Two Presentations On Innovative Drug-Fc Conjugate, CD388, At The 2024 OPTIONS XII For The Control Of Influenza Conference
Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced two presentations at OPTIONS XII for the Control of Influenza conference, to be held September 29 through October 2, 2024 in Brisbane, Australia. The presentations, one oral and one poster, will highlight safety and pharmacokinetic (PK) data from clinical studies of CD388, Cidara's influenza drug-Fc conjugate (DFC) candidate.
Cidara Therapeutics, Inc.（纳斯达克:CDTX）是一家生物技术公司，利用其专有的Cloudbreak平台开发药物-Fc结合物（DFC）免疫疗法，旨在挽救生命并改善面临严重疾病的患者的治疗标准。今天宣布将在2024年9月29日至10月2日在澳洲布里斯班举行的OPTIONS XII控制流感研讨会上进行两次演讲。其中一次是口头演讲，另一次是海报展示，重点介绍CD388的临床研究中的安全性和药代动力学（PK）数据，CD388是Cidara的流感药物-Fc结合物（DFC）候选药物。